This application describes a 5-year plan to establish an independent career in academic pediatric pulmonology. The candidate's long-term goal is to develop an interdisciplinary research program focusing on microbial pathogenesis in lung infections while maintaining a clinical practice encompassing 20% of the candidate's time. The training environment consists of the laboratory of Dr. Samuel Miller at the University of Washington and the Pulmonary Division at Children's Hospital & Regional Medical Center, both in Seattle. The candidate will expand his research expertise through a project with basic and translational components, augmented by collaboration and advising from senior scientists and clinicians. The formation of bacterial biofilms is associated with antibiotic resistance. One of the best-studied model systems is the chronic Pseudomonas aeruginosa airway infection in people with cystic fibrosis (CF). P. aeruginosa infects CF airways as a biofilm, and it adapts to the CF airway environment during infection. These adaptations affect bacterial responses to antibiotics. Preliminary data demonstrate that P. aeruginosa responds specifically to subinhibitory concentrations of the antibiotic tobramycin with increased biofilm formation. Tobramycin-induced biofilms are more resistant to further antibiotic challenge. Preliminary evidence suggests a role for two cell signaling systems, quorum sensing and the cyclic diguanylate pathway, in the response to tobramycin. Published data led to the hypothesis that responses to tobramycin vary among CF P. aeruginosa isolates, with variable effects on progression of lung disease. We propose to determine the molecular mechanism of the biofilm response of a laboratory strain of P. aeruginosa to tobramycin using available resources (Specific Aim 1). The clinical relevance of this response will then be determined by examining archived clinical isolates from CF patients, as well as environmental strains of P. aeruginosa (Specific Aim 2). The ultimate goal of this project is to identify novel therapeutic targets to inhibit the development of antibiotic resistance, and to aid eradication of chronic infections. The techniques and environments in this proposal are ideal for preparing for a career in the study of lung infections in children.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08AI066251-02
Application #
7091539
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Taylor, Christopher E,
Project Start
2005-07-15
Project End
2008-05-31
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
2
Fiscal Year
2006
Total Cost
$126,306
Indirect Cost
Name
University of Washington
Department
Pediatrics
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Hocquet, Didier; Petitjean, Marie; Rohmer, Laurence et al. (2016) Pyomelanin-producing Pseudomonas aeruginosa selected during chronic infections have a large chromosomal deletion which confers resistance to pyocins. Environ Microbiol 18:3482-3493
McCaughey, Gerard; Gilpin, Deirdre F; Schneiders, Thamarai et al. (2013) Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions. Antimicrob Agents Chemother 57:5406-14
Hoffman, Lucas R; Richardson, Anthony R; Houston, Laura S et al. (2010) Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway. PLoS Pathog 6:e1000712
Christen, Matthias; Kulasekara, Hemantha D; Christen, Beat et al. (2010) Asymmetrical distribution of the second messenger c-di-GMP upon bacterial cell division. Science 328:1295-7
Elliott, Danielle; Burns, Jane L; Hoffman, Lucas R (2010) Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 54:3024-6
Hoffman, Lucas R; Kulasekara, Hemantha D; Emerson, Julia et al. (2009) Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros 8:66-70
D'Argenio, David A; Wu, Manhong; Hoffman, Lucas R et al. (2007) Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol 64:512-33